Guangdong MPA Adds 27 Designated Hospitals to the GBA Connect Scheme

On December 26, 2025, Guangdong’s Ministry of Public Administration (MPA) and the Guangdong Provincial Drug Administration (GPDCA) unveiled the fourth batch of designated hospitals under the Greater Bay Area (GBA) Connect Scheme. This update, effective immediately, adds 27 new hospitals to the list, while removing one.

For manufacturers of Hong Kong and Macau-approved products, this expanded network provides even greater access to China’s healthcare market through the GBA Connect Scheme. The initiative continues to accelerate the adoption of innovative therapies, specifically those addressing urgent clinical needs, by facilitating smoother entry into China's hospitals.

What’s New in the GBA Connect Scheme

With the addition of 27 new hospitals, the network now covers major cities like Guangzhou, Shenzhen, Zhuhai, Foshan, and others. This expansion presents more opportunities for manufacturers to collaborate with healthcare providers in the GBA and fast-track the clinical adoption of their products.

A snapshot of the key updates is provided below:

27 hospitals across Guangzhou, Shenzhen, Zhuhai, Foshan, Huizhou, Dongguan, Zhongshan, and Zhaoqing — Click here to view the list of added GBA Connect Scheme hospitals.
1 hospital removed: Foshan C-MER Lin Shunchao Eye Hospital.
Hospital applications for Hong Kong/Macau-approved products can now be submitted for urgent clinical needs.
Overseas manufacturers are encouraged to engage with hospitals to validate clinical demand, collaborate with clinicians, and support regulatory submissions.
Optional pre-approval filing can streamline future hospital applications, reducing preparation time. Contact Cisema today to learn how.

What Is the GBA Connect Scheme?

The GBA Connect Scheme enables Guangdong’s designated hospitals to introduce Hong Kong and Macau-approved drugs and medical devices when there is an urgent clinical need. As of December 2025, 63 drugs and 77 medical devices have been authorized for use across 71 designated healthcare institutions, underscoring strong demand and the scheme’s growing impact.

Hospitals within the scheme act as the formal applicants, submitting product details to the Guangdong authorities for approval. This streamlined process accelerates patient access to innovative therapies, facilitating faster entry for foreign products into China’s healthcare system.

How Manufacturers Can Benefit from the GBA Connect Scheme

Manufacturers can unlock significant opportunities through the GBA Connect Scheme by directly engaging with designated hospitals. To maximize success, we recommend focusing on the following strategies:

Engage Designated Hospitals: Prioritize departments that are most likely to validate urgent clinical need and ensure that clinical and economic evidence is well-prepared for hospital presentations.
Use Pre-Approval Filing Strategically: When appropriate, submit product data early to streamline future submissions and minimize delays.
Prepare for Trials and Pricing: Allocate resources for trial use and engage in early-stage pricing and procurement negotiations.
Ensure Compliance and Readiness: Align all product documentation with Guangdong’s regulatory requirements, focusing on traceability and risk control measures to ensure full compliance.
Consider Scaling Pathways: Leverage initial hospital engagements to broaden your product’s reach within the GBA, with the goal of eventually pursuing national registration for long-term growth.

Final Thoughts

The addition of 27 new hospitals under the GBA Connect Scheme strengthens the channel for Hong Kong and Macau-approved products to enter China's healthcare market. By taking a proactive approach — validating clinical needs, supporting trials, and preparing complete regulatory documentation — manufacturers can shorten time-to-market and boost the adoption of their products across the region

Cisema provides comprehensive support for Hong Kong drug registration, medical device listings, and hospital engagement strategies. We also handle optional pre-approval filings and streamline the submission process, ensuring faster market access and smoother scale-up.

Ready to seize the opportunity with the GBA Connect Scheme? Contact Cisema today to craft your pathway strategy and fast-track your product’s success in the GBA.

Further Information

Cisema provides specialized support for manufacturers navigating the GBA Connect Scheme. For more information on how to access these designated hospitals, please visit our service pages:

Appendix: Fourth Batch of New GBA Connect Scheme Hospitals (27)

Guangzhou GBA Connect Scheme Hospitals (广州):

Southern Medical University Zhujiang Hospital (南方医科大学珠江医院)
Guangzhou Medical University Affiliated Brain Hospital (广州医科大学附属脑科医院)
Guangdong Second Provincial People’s Hospital (广东省第二人民医院)
Guangzhou Xinshi Hospital (广州新市医院)
Guangzhou Development Zone Hospital (广州开发区医院 / 广州市黄埔区人民医院)
Guangzhou Taihe Oncology Hospital (广州泰和肿瘤医院)

Shenzhen GBA Connect Scheme Hospitals (深圳):

Shenzhen People’s Hospital (深圳市人民医院)
Shenzhen Children’s Hospital (深圳市儿童医院)
Shenzhen Longgang ENT Hospital (深圳市龙岗区耳鼻咽喉医院)
Sun Yat-Sen University Affiliated Eighth Hospital (Shenzhen Futian) (中山大学附属第八医院（深圳福田）)
Shenzhen Qianhai Taikang Hospital (深圳前海泰康医院)
Shenzhen University General Hospital (深圳大学总医院)
Shenzhen Yantian District People’s Hospital (深圳市盐田区人民医院)

Zhuhai GBA Connect Scheme Hospitals (珠海):

Zhuhai Integrated Chinese and Western Medicine Hospital (珠海市中西医结合医院)

Foshan GBA Connect Scheme Hospitals (佛山):

Foshan First People’s Hospital (佛山市第一人民医院)
Southern Medical University Eighth Affiliated Hospital (Foshan Shunde First People’s Hospital) (南方医科大学第八附属医院（佛山市顺德区第一人民医院）)
Foshan Nanhai District People’s Hospital (佛山市南海区人民医院 / 华南理工大学附属第六医院)
Guangdong Provincial People’s Hospital Nanhai Branch (广东省人民医院南海医院)
Heyou Zhizhen Hospital (和祐至臻医院)

Huizhou GBA Connect Scheme Hospitals (惠州):